SEEGNAL INC. ANNOUNCES CHANGE IN AUDITOR

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

CALGARY, AB, March 9, 2026 /CNW/ - Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, announces a change of the Company's auditor effective immediately. At the request of the Company, Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited (the "Former Auditor") has resigned as auditor of the Company effective March 9, 2026. The audit committee and board of directors of the Company have appointed Zeifmans LLP as the successor auditor, effective March 9, 2026 (the "Successor Auditor") until the close of the next annual general shareholder meeting of the Company. The Company has sent a Notice of Change of Auditor (the "Notice") to the Former Auditor and to the Successor Auditor and has received a letter from each, addressed to the securities commissions in each of Alberta, Ontario and British Columbia stating that they agree with the information contained in the Notice. The Notice together with the letter from the Former Auditor and the letter from the Successor Auditor have been reviewed and approved by the Company's audit committee and its board of directors and are available on www.sedarplus.ca. There were no disagreements or unresolved issues between the Company and the Former Auditor on any matter of audit scope or procedures, accounting principles or policies, or financial statement disclosure. It is the Company's opinion that there have been no "reportable events" (as defined in National Instrument 51-102 – Continuous Disclosure Obligations) between the Company and the Former Auditor.

About Seegnal

Seegnal is a public company that aims to solve one of the top causes of death and injuries in the modern world – Adverse Drug Effects (ADEs). Seegnal's Clinical Decision Support system introduces a paradigm shift in the approach to this problem by implementing a new elevated Patient-Centric Standard. Seegnal's SaaS technology exclusively integrates at the point-of-care, unique patient-specific data like genetics, results of lab tests, ECG, smoking, allergies, food, gender, age, and the effects of many concomitant medications, while reducing the current alert load for clinicians by over 90%. In practice, clinicians using Seegnal eHealth complete their prescription workflow with limited interruption, saving time and fatigue. Similarly, patients enjoy more tailored medication and improved safety, leading to better quality of life, due to the precision of alerts with up to 98% accuracy.  Institutions reported a reduction in admissions, medication consumption, and ample time savings in prescription renewals. Seegnal eHealth is marketing its SaaS-based platform in the State of Israel (where recently the Ministry of Health has adopted Seegnal's patient-specific standard as the new standard in governmental hospitals), the UAE, the United Kingdom, the United States, and Poland. The platform is currently a "standard of care" system for over 10,000 clinicians in Israel, used on a daily basis for prescribing medications to their patients. 

See www.seegnal.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

SOURCE Seegnal Inc.

View original content: http://www.newswire.ca/en/releases/archive/March2026/09/c2455.html